Thank you for the opportunity to make some opening remarks on the substance of the statutory instrument. I hope that they will be helpful, because the regulations are complicated. I will then address the error.
The SI relates to the control process by which biocidal products, which are mainly used to control pests or bacteria, or to protect people, animals, materials or articles from pests and bacteria, are considered for access to the Great Britain market. The overall purpose of the SI is to put in place temporary measures to allow the Health and Safety Executive to process the large number of applications that were received under the transitional arrangements following EU exit.
The GB regime—as I will refer to it—ensures that any products that are placed on the GB market are safe to use and efficacious. Suppliers or manufacturers of biocidal products have to apply for authorisation from the HSE to be able to sell or use their products, and must do so within specific timeframes. With the transitional arrangements under the GB regime, the HSE has received a very large influx of applications, which it cannot deal with within the legal deadlines as they stand. The SI purports to extend the deadlines for certain applications.
The authorisation procedure in the GB regime depends on the type of application that is being made. The changes made by the SI will affect the legal deadlines across various applications.
The Health and Safety Executive is confident that amending the regulations in the way that is proposed will allow it to process the applications that it has received within the extended deadlines. Applications will be processed on a rolling basis. Work has started already, and it is expected that the majority will have been processed before 31 December 2027—the new deadline.
The Scottish ministers consider that the situation should have been foreseeable. The events that have made the SI necessary were not of our choosing. However, given the situation at hand, we think that not agreeing to the extension, and thereby hindering the operability of the new GB regime, would pose a greater risk to the environment, public health, businesses, consumers and the economy than allowing the temporary extension. If consent were not granted, the practical implication would be that, as current evaluation deadlines pass, legally, large numbers of biocidal products would need to be phased off the GB market.
Thank you for giving me the time to set that out. I will now briefly address the error in the notification and the notification summary that we submitted to the committee on 23 September. The notification does not accurately describe one of the proposed legislative changes—it is a minor change compared with the overall effect of the SI.
I will explain it for the record, but this is very complicated, so please bear with me. The original notification stated that the SI introduced into the GB regime
“a new transitional provision”
that would
“allow applications to change or modify an authorisation made under the EU”
regime before the implementation day and that that would be transferred to the GB regime
“provided the application and relevant information have been resubmitted.”
However, the notification should have said that the new transitional provision will allow applications made to the HSE before implementation day, specifically under regulation 414/2013, which are subject to the simplified authorisation procedure, and for biocidal products that are identical to another product that is already authorised or under assessment, and that those should be resubmitted and considered for authorisation under the GB regime.
My officials inform me that that was a result of an oversight in drafting and that we let the committee know as soon as we could. I express my apologies for that oversight in what is clearly a very technically complicated piece of work.
10:45